Welcome to our dedicated page for Rapport Therapeutics news (Ticker: RAPP), a resource for investors and traders seeking the latest updates and insights on Rapport Therapeutics stock.
Rapport Therapeutics Inc (RAPP) is a clinical-stage biopharmaceutical company pioneering precision therapies for central nervous system disorders. This page aggregates official press releases, financial updates, and breaking news related to RAP-219 clinical trials, partnership announcements, and regulatory milestones.
Investors and industry professionals will find timely updates on RAPP's innovative receptor-associated protein (RAP) technology platform and its application in treating refractory epilepsy, neuropathic pain, and bipolar disorder. The curated news collection enables efficient tracking of the company's progress in neuroscience drug development.
Content includes earnings reports, clinical trial results, executive leadership updates, and scientific presentations. All materials are sourced directly from verified company communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Rapport Therapeutics' latest developments in precision medicine. Check regularly for updates on pipeline advancements and strategic initiatives shaping the future of CNS disorder treatments.
Rapport Therapeutics (NASDAQ: RAPP) has announced positive Phase 1 data for RAP-219, its CNS disorder treatment candidate. The PET trial demonstrated that RAP-219 achieved and exceeded target receptor occupancy within five days of dosing, supporting the dosing regimen in the ongoing Phase 2a focal epilepsy trial.
Key findings from trials involving 100 healthy volunteers showed RAP-219 was generally well-tolerated with no serious adverse events, and only 3% treatment discontinuations. The drug demonstrated favorable tolerability across various dosing regimens, with no sedation or motoric impairments observed.
The PET trial confirmed TARP8-containing AMPA receptors are enriched in the hippocampus and cerebral cortex, with minimal presence in the cerebellum and brain stem. The MAD-2 trial showed successful dose escalation and faster therapeutic level achievement. The company expects topline data from the ongoing Phase 2a trial in focal epilepsy by mid-2025.
Rapport Therapeutics (NASDAQ: RAPP) presented data showing a significant correlation between reductions in RNS-measured long episodes (LEs) and clinical seizures in focal epilepsy patients. The analysis revealed that a 30% reduction in LEs corresponds to a ≥50% reduction in clinical seizures, validating their biomarker approach for ongoing trials.
The company presented additional findings at the American Epilepsy Society Annual Meeting, including Phase 1 results showing RAP-219 was well-tolerated at target therapeutic exposures, food interaction studies indicating flexible dosing options, and preclinical data demonstrating dose-dependent antiseizure effects. Rapport's Phase 2a proof-of-concept trial for RAP-219 is ongoing with topline data expected in mid-2025.
Rapport Therapeutics (NASDAQ: RAPP) announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (December 6-10, 2024, Los Angeles). The company will present new data on the correlation between long episode frequency reduction and clinically meaningful reduction in patient-reported seizures, derived from an RNS® System study.
The presentations include data from their Phase 2a trial of RAP-219, their lead product candidate for drug-resistant focal epilepsy. Four poster presentations will cover antiseizure effects, pharmacokinetics, safety, and tolerability studies. A Scientific Exhibit Room session will showcase these posters along with additional information about RAP-219's development and trial design.
Rapport Therapeutics (NASDAQ: RAPP) reported Q3 2024 financial results and business updates. The company's lead program RAP-219 continues Phase 2a trials for focal epilepsy, with topline data expected mid-2025. The FDA placed a clinical hold on their Investigational New Drug Application for diabetic peripheral neuropathic pain. Four new biotech leaders joined the Board of Directors. Q3 financial results showed a net loss of $17.5 million, with R&D expenses of $15.5 million and G&A expenses of $6.1 million. The company ended Q3 with $320.7 million in cash and equivalents, expected to fund operations through 2026.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule precision medicines for CNS disorders, has announced its participation in two major healthcare conferences in November 2024. The company will engage in fireside chats at the Stifel Healthcare Conference in New York City on November 18 at 1:15pm ET, and the Jefferies London Healthcare Conference on November 20 at 4:00pm GMT/11am ET. Live and archived webcasts will be available on the company's investor relations website.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company focusing on CNS disorders, announced presentations at two upcoming epilepsy conferences. At the 15th Annual European Epilepsy Congress in Rome (Sept. 7-11, 2024), they will present on the novel design of a Phase 2a proof-of-concept trial for RAP-219 in drug-resistant focal epilepsy. At the 2024 Epilepsy Foundation Pipeline Conference in Atlanta (Sept. 25-26, 2024), they will discuss RAP-219's mechanism of action and the trial design.
Presentations include:
- EEC: 'Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219' (Sept. 08, 2024)
- Pipeline Conference: 'RAP-219 a novel, potent, and selective negative modulator of AMPAR TARPγ8' (Sept. 26, 2024)
Presentations will be available on Rapport's website after the conferences.
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule medicines for CNS disorders, has announced its participation in two upcoming investor conferences. The company will present at:
1. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 5, 2024, at 4:50 pm ET.
2. TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on September 26, 2024, at 11:40 am ET.
A live and archived webcast of the Morgan Stanley Conference fireside chat will be available on the company's investor relations website. This presentation offers investors an opportunity to gain insights into Rapport Therapeutics' progress in developing innovative treatments for central nervous system disorders.
Contineum Therapeutics (Nasdaq: CTNM) reported Q2 2024 financial results and recent business highlights. Key points include:
- Strong cash position of $219 million at Q2 end
- Appointed Troy Ignelzi and Sarah Boyce to Board of Directors
- Strengthened management team with John Healy and Kristina Haeckl
- Enrollment on track for PIPE-307 Phase 2 VISTA trial in RRMS
- Published preclinical and clinical results on PIPE-307 and PIPE-791
- Completed IPO with net proceeds of $107.9 million
Financial results:
- R&D expenses: $7.9 million (Q2 2024) vs $9.5 million (Q2 2023)
- G&A expenses: $3.0 million (Q2 2024) vs $1.6 million (Q2 2023)
Rapport Therapeutics (RAPP) reported Q2 2024 financials and provided a business update. Key highlights include:
1. Completed IPO, raising $174.4 million in gross proceeds
2. Phase 2a trial of RAP-219 in focal epilepsy on track for Q3 2024 initiation, with topline data expected mid-2025
3. Two additional proof-of-concept trials for RAP-219 planned: peripheral neuropathic pain (2H 2024) and bipolar disorder (2025)
4. Q2 2024 net loss: $18.1 million
5. Cash position: $336.1 million, expected to fund operations through end of 2026
6. Advancing preclinical programs, including RAP-199 and two nAChR discovery-stage programs
Rapport Therapeutics (Nasdaq: RAPP) will present preclinical data on RTX-1738, an analog to their lead product candidate RAP-219, at the IASP 2024 World Congress on Pain in Amsterdam. The poster presentation, scheduled for August 6, 2024, will showcase RTX-1738's analgesic activity across various acute and chronic pain models.
RTX-1738 is an AMPAR negative allosteric modulator designed to target TARPγ8, a receptor associated protein. This approach aims to achieve neuroanatomical specificity in treating central nervous system disorders. The company's lead candidate, RAP-219, is currently in a Phase 2a trial for drug-resistant focal epilepsy. Rapport plans to initiate additional Phase 2a trials for RAP-219 in peripheral neuropathic pain and bipolar disorder in late 2024 and 2025, respectively.
FAQ
What is the current stock price of Rapport Therapeutics (RAPP)?
What is the market cap of Rapport Therapeutics (RAPP)?
